Research  >  Areas of Focus  >  Research Platforms  >  Combined Health Services Sciences

Scientist profiles S-Z

SRI Profiles

Maureen E. Trudeau, MA, MD, FRCPC

Affiliate scientist

Sunnybrook Health Science Centre
2075 Bayview Ave., Room T2 023
Toronto, ON
M4N 3M5

Phone: 416-480-5145
Fax: 416-480-6002

Administrative assistant: Yvonne Rohlehr
Phone: 416-480-5145
Fax: 416-480-6002


  • B.Sc., 1972, University of Toronto, Canada
  • MA, 1973, math, York University, Canada
  • MD, 1981, U of T, Canada
  • FRCPC, 1986, Royal College of Physicians and Surgeons, Canada

Appointments and Affiliations:

  • Affiliate scientist, Evaluative Clinical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute
  • Head, division of medical oncology and hematology, Sunnybrook Health Sciences Centre
  • Head, systemic therapy program, Odette Cancer Centre, Sunnybrook
  • Professor, department of medicine, faculty of medicine, U of T
  • Associate member, Institute of Medical Science, U of T
  • Co-chair, breast cancer site group, program in evidence-based care, Cancer Care Ontario

Research Foci:

  • Breast cancer
  • Prognostic factors
  • New drugs
  • Clinical trials
  • Survivorship

Research Summary:

Dr. Trudeau's research interests cover the spectrum of breast cancer from prevention to treatment and palliative care. To date, her research has centred on the following:

  • clinical trials in prevention, and adjuvant and metastatic disease, including investigational new drugs
  • a study of the quality of life and general health of long-term survivors of breast cancer
  • guidelines for the treatment of breast cancer and systemic therapy.

Her research findings have been published in many journals, including The New England Journal of Medicine, Journal of Clinical Oncology and Breast Cancer Research and Treatment.

In addition, Dr. Trudeau participates in clinical trials through the National Cancer Institute of Canada-Clinical Trials Group ,(NCIC-CTG), the National Surgical Adjuvant Breast and Bowel Project and in studies supported by grants from industry. She has also chaired several studies in breast cancer through NCIC-CTG.

The use of new drugs remains a strong area of research interest for Dr. Trudeau. She is investigating the use of epirubicin and Taxotere as a neoadjuvant therapy, and has collected tissue biopsies for microarray analysis of factors to predict drug sensitivity and resistance. This trial has formed the basis for further research in RNA degradation.

As co-chair of the Breast Disease Site Group, Dr. Trudeau has authored many guidelines on the treatment of breast cancer, which have influenced drug-funding decisions provincially and nationally.

Selected Publications:

See current publications list at PubMed.